Vistagen announces publication in cells demonstrating av-101's potential for treating levodopa-induced dyskinesia in patients with parkinson's disease

South san francisco, calif.--( business wire )--vistagen (nasdaq: vtgn) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced the publication of positive results from a preclinical study of the effects of av-101, its oral nmda receptor glycine site antagonist, in a widely used mptp non-human primate model for reproducing motor complications of parkinson's disease (pd), including dyskinesia (sudden uncontrolled movements) observed in pd patients treated with levodopa (l-dopa). findings from the preclinical study were published in the international, peer-reviewed journal, cells . in the preclinical study, av-101 reduced l-dopa-induced dyskinesias (lid) by about 25% while maintaining the antiparkinsonian response to l-dopa.
VTGN Ratings Summary
VTGN Quant Ranking